News | May 11, 2022
Cipla posts consolidated PAT of Rs. 362.07 crore in Q4 FY2022
Cipla has reported consolidated financial results for the period ended March 31, 2022
Cipla has reported consolidated financial results for the period ended March 31, 2022
The capex for FY22 stood at Rs 145 crore and is expected to be in the range of Rs 250-350 crore for the entire FY23 which would be funded through a mix of internal accruals and debt
Survey findings released in advance of World Lupus Day on May 10
The increase in PAT is driven by higher sales and lower marketing and depreciation charge vs the same period last year
In the UK, Bartec has been synonymous with Mediso products for 18 years, proof of a successful partnership
The company dispatched the first batch of essential medicines worth US $ 30,000 to Ukraine through its embassy in New Delhi
Move brings together AstraZeneca and Alexion colleagues in a purpose-built facility in Kendall Square, Cambridge, MA, a world-leading life sciences hub
Funds will be allocated to accelerate rapid production and high-end curation of whole genome sequences for its clinical application
The plant is expected to start commercial operations from Q4FY24
Cysoni is a bionic device that paces the heart with real-time respiratory modulation
Subscribe To Our Newsletter & Stay Updated
